To view the PDF file, sign up for a MySharenet subscription.

ASPEN PHARMACARE HOLDINGS LIMITED - Renewal of Cautionary

Release Date: 05/09/2013 16:00
Code(s): APN     PDF:  
Wrap Text
Renewal of Cautionary

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
("Aspen" or "the Company")

Renewal of Cautionary Announcement- Discussions with GSK

Shareholders are referred to the cautionary announcement released by
Aspen on 18 June 2013 (and subsequent renewals) in which shareholders
were advised of discussions between Aspen and GlaxoSmithKline plc
(“GSK”) in respect of a possible transaction in terms whereof:

•   Aspen Global Incorporated, a wholly owned subsidiary of Aspen, will
    acquire from GSK the Arixtra and Fraxiparine/Fraxodi brands (“the
    Brands”) and business worldwide, except in China, Pakistan and
    India; and

•   Aspen will acquire from GSK a specialised sterile production site
    which manufactures the Brands at Notre Dame de Bondeville, France
    (“the Site”);

    (collectively “the Proposed Transaction”); and

•   Aspen’s offer to GSK in respect of the Proposed Transaction is
    approximately GBP 700 million of which approximately GBP 100 million
    is for inventory.


Shareholders are advised that discussions regarding the Proposed
Transaction remain ongoing and may have a material effect on the price
of Aspen’s securities if successfully concluded and accordingly
shareholders are advised to continue exercising caution when dealing
in Aspen’s securities.


Durban
5 September 2013

Sponsor: Investec Bank Limited

Date: 05/09/2013 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story